Bookkeeping for Medical Device Reprocessors: When the FDA Calls You a Manufacturer

The Business That Legally Becomes a "Manufacturer" Without Ever Making a Device​

A hospital finishes a procedure and drops a used-but-technically-"single-use" surgical stapler, pulse oximeter sensor, or catheter into a bin. Instead of landfill, that device gets picked up, shipped to a specialized facility, cleaned, tested, re-sterilized, repackaged, and sold back to a hospital — sometimes the same one — at 30% to 50% off the price of a new unit.

That's third-party medical device reprocessing, and it's a bigger business than most people realize: the U.S. reprocessed-device market is worth roughly $810 million in 2026 and is projected to climb past $2.3 billion by 2031. Hospitals and surgical centers saved an estimated $495.5 million in 2025 alone by buying reprocessed devices instead of new ones, according to industry association figures — savings substantial enough that large health systems now run reprocessing into their standard supply-chain playbook.

Here's the part that trips up new entrants to this niche: the moment you reprocess a "single-use" device for resale, the FDA doesn't treat you like a repair shop or a refurbisher. It treats you exactly like the original manufacturer — same premarket clearance burden, same quality system rules, same recall and adverse-event obligations, for a device you didn't design and didn't build the first time. That regulatory reality reshapes almost every line on a reprocessor's books, from inventory costing to liability reserves. If you're running — or thinking about starting — a reprocessing operation, here's what the accounting actually looks like.

Why the FDA Calls You a "Manufacturer" on Day One​

Under FDA rules, a "single-use device" (SUD) is a device labeled for one use only. When a hospital or a third-party company reprocesses one for reuse, the FDA doesn't create a lighter-touch category for reprocessors. Instead, it holds them to the identical bar as the company that made the device in the first place:

• 510(k) premarket notification. For most device types that originally required FDA clearance, a reprocessor must separately demonstrate that its reprocessed version is substantially equivalent to a legally marketed device — a distinct submission and validation package per device model, not a blanket approval for the business.
• Quality Management System Regulation (QMSR). As of February 2, 2026, the FDA's QMSR — codified at 21 CFR Part 820 — replaced the older Quality System Regulation and now incorporates ISO 13485:2016 by reference, with a handful of FDA-specific additions layered on top. Every reprocessor has to run a quality management system that satisfies both the international standard and the FDA's add-ons.
• Medical Device Reporting (MDR). Reprocessors must report adverse events and file an annual certification stating either that all required MDR reports were submitted or that none were reportable that year.
• Labeling and UDI. Reprocessed devices must be clearly labeled as reprocessed, with instructions for use, and carry Unique Device Identification per 21 CFR Part 830 — which means every unit needs traceable lot and serial data from intake to resale.

None of that is optional paperwork you can defer. Ship a reprocessed device without a required 510(k) on file, or let your QMSR certification lapse, and the FDA can force you to stop shipping — which is a cash-flow emergency, not just a compliance footnote.

Costing a Product You Didn't Originally Manufacture​

Standard retail or light-manufacturing chart of accounts don't map cleanly onto reprocessing. The inventory actually moves through three distinct states, and each one needs its own cost bucket:

1. Collected/explanted inventory — used devices received from hospitals, often at zero or near-zero purchase cost, but with real logistics costs attached (collection bins, courier pickup, chain-of-custody paperwork).
2. Work-in-process (reprocessing) — cleaning validation, sterilization, functionality testing, and repackaging labor and materials. This is where most of the real cost sits, and it varies enormously by device complexity: a simple compression sleeve costs far less to validate and reprocess than an electrophysiology catheter.
3. Finished reprocessed inventory — packaged, UDI-labeled, sterilized units with a shelf life (sterility has an expiration date, much like a food product), ready for sale.

Track cost per device family separately rather than blending everything into one COGS number. Because every device type needs its own 510(k) and its own validation protocol, your margin story is really a portfolio of small product lines, not one undifferentiated "reprocessing" revenue stream. A useful KPI here is cost-to-reprocess as a percentage of new-unit price per device family — it tells you immediately which device lines are worth the regulatory overhead and which ones are marginal.

Where the Big, Non-Obvious Costs Hide​

A few cost categories are easy to underestimate if you're building a chart of accounts for this business for the first time:

• 510(k) submission and validation studies. Cleaning validation (proving all biological material is removed), sterilization validation (confirming microbial kill), and functionality testing after reprocessing are substantial, recurring costs per device model — not a one-time setup expense. Budget for these as an ongoing cost of adding or maintaining product lines, generally expensed as incurred rather than capitalized, since the studies support regulatory compliance for existing product lines rather than creating a separable long-lived asset.
• QMSR/ISO 13485 transition and maintenance costs. Documentation systems, internal audits, and third-party certification audits recur annually. Industry estimates put the audit fee itself at only 15–30% of total compliance spend — implementation and internal process work is the larger 60–75% share, and that's ongoing labor cost, not a one-off.
• Facility and equipment depreciation. Sterilization chambers, cleanroom build-outs, and validated cleaning equipment are real capital expenditures with FDA-mandated maintenance and calibration schedules — track them separately from general equipment because their depreciation and compliance costs are inseparable.
• Traceability systems. UDI tracking from device intake through resale isn't a nice-to-have — it's what makes a recall possible. Whatever inventory or lot-tracking system you use needs to hold up to an FDA facility inspection, so budget for a system that actually supports serial/lot-level audit trails, not a spreadsheet.

Product Liability: The Reserve Line Most New Reprocessors Skip​

Because the FDA treats you as the manufacturer of a device that already had one full life cycle, your product liability exposure is structurally different from a typical distributor's. If a reprocessed device fails, the reprocessor — not the original OEM — is the manufacturer of record for that failure.

That means a loss-contingency reserve for product liability isn't optional risk management; it's a real balance sheet line that should scale with unit volume and device risk class (a reprocessed compression sleeve carries different risk than a reprocessed cardiac catheter). Pair the reserve with adequate product liability insurance, and revisit both every time you add a new device family — the FDA's own MDR annual-certification requirement effectively forces you to formally account for adverse events every single year, so your reserve estimate has a built-in review cadence already.

Revenue Recognition and Working Capital​

Most reprocessors sell B2B to hospitals and health systems, which typically means invoice terms of net-30, -60, or even -90 — similar cash-flow lag to other regulated B2B verticals. Revenue is generally recognized at shipment or delivery, consistent with standard product-sale recognition, but the sterile shelf life on finished inventory adds a wrinkle: units that age past their sterility date without selling become write-offs, not slow-moving stock you can eventually discount and clear. Track aging on finished reprocessed inventory the way a bakery tracks aging on perishables, not the way a hardware distributor tracks aging on tools.

A Practical Chart-of-Accounts Starting Point​

Because the business really runs as a portfolio of narrow, regulated product lines rather than one undifferentiated service, a chart of accounts that lumps everything into generic "COGS" and "revenue" buckets will hide the numbers you actually need to make decisions. A structure that holds up better looks something like this, repeated per device family:

• Revenue:Reprocessing:<DeviceFamily> — sales for that specific device type
• COGS:Collection:<DeviceFamily> — courier/logistics cost of getting used units back from hospitals
• COGS:Validation:<DeviceFamily> — cleaning, sterilization, and functionality-testing labor and materials
• COGS:Packaging:<DeviceFamily> — sterile packaging and UDI labeling
• Expenses:Regulatory:510k:<DeviceFamily> — submission and validation-study costs for that model
• Expenses:Regulatory:QMSR — shared quality-system audit, documentation, and certification costs (not device-specific)
• Liabilities:Reserves:ProductLiability:<RiskClass> — loss-contingency reserves grouped by device risk class rather than by family, since risk class (not device type) is what should drive reserve sizing
• Assets:Inventory:Collected / :WIP / :Finished:<DeviceFamily> — the three-stage inventory split described above, so a finished unit sitting past its sterility date is visibly distinct from a unit still mid-process

Keeping validation and regulatory costs in their own expense accounts, separate from routine COGS, also makes it far easier to answer the question that actually determines whether a device family is worth keeping: does the margin on that product line cover its share of recurring regulatory overhead, or is it being subsidized by higher-margin lines?

Insurance and Entity Structure​

Because FDA treats a reprocessor as the manufacturer of record, general liability coverage sized for a typical distributor or service business is usually inadequate. Product liability coverage needs to be underwritten with the understanding that the business bears manufacturer-level exposure for a device it didn't originally design — and premiums should be expected to scale with both unit volume and the risk class of the devices in the portfolio, not just total revenue.

On the entity side, most reprocessors organize as an LLC or S-corp like other regulated small manufacturers, but it's worth discussing with counsel whether device families with meaningfully different risk profiles (say, low-risk compression sleeves versus higher-risk cardiac catheters) warrant separate legal entities or subsidiaries to contain liability exposure. That's a legal decision, not an accounting one, but your books should be structured — per the chart of accounts above — so that a future entity split wouldn't require rebuilding your cost tracking from scratch.

Keep the Regulatory Complexity Out of Your Books' Way​

Running a business where the FDA calls you a manufacturer for a product you didn't originally build means your books need to answer questions a typical small business never faces: cost per device family, liability reserves by risk class, and compliance spend that recurs annually rather than once. Plain-text accounting in Beancount makes that kind of structured, auditable tracking straightforward — every device family, cost center, and reserve account lives in version-controlled text you can query, diff, and hand to an auditor without wrestling a proprietary export format. Get started for free and see why technical teams building in regulated niches are switching to plain-text accounting.